A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma.

被引：0
作者：
Shaikh, Saba
Zang, Yan
Hanmer, Janel
Wang, Hong
Lin, Yan
Davar, Diwakar
Zarour, Hassane M.
Kirkwood, John M.
Najjar, Yana G.
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21506
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase I/II trial of BKM120 combined with vemurafenib (PLX4032) in BRAFV600E/k mutant advanced melanoma.
    Kantor, Andrea
    Daud, Adil
    Munster, Pamela N.
    Ea, Roth
    Algazi, Alain Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Patients with metastatic melanoma treated with vemurafenib as monotherapy or in combination with cobimetinib.
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    Mesti, Tanja
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma
    Atkins, Michael B.
    Carlino, Matteo S.
    Hill, Andrew G.
    McNeil, Catriona M.
    Long, Georgina V.
    Atkinson, Victoria
    Cebon, Jonathan S.
    Jameson, Michael B.
    Hwu, Wen-Jen
    Thompson, John A.
    Anderson, James
    Moreno, Blanca Homet
    Ibrahim, Nageatte
    Ribas, Antoni
    CANCER RESEARCH, 2017, 77
  • [44] Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib plus Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
    Piejko, Karolina
    Cybulska-Stopa, Bozena
    Zietek, Marcin
    Dziura, Robert
    Galus, Lukasz
    Kempa-Kaminska, Natasza
    Ziolkowska, Barbara
    Rutkowska, Ewa
    Kopcinski, Tomasz
    Kubiatowski, Tomasz
    Bal, Wieslaw
    Suwinski, Rafal
    Mackiewicz, Jacek
    Kaminska-Winciorek, Grazyna
    Czarnecka, Anna M.
    Rutkowski, Piotr
    TARGETED ONCOLOGY, 2023, 18 (02) : 235 - 245
  • [45] Patient-reported outcomes (PROs) from the phase Ill IMspire150 trial of atezolizumab (A) plus cobimetinib (C) plus vemurafenib (V) in patients (pts) with BRAFV600+melanoma.
    Lewis, Karl D.
    Robert, Caroline
    Ascierto, Paolo Antonio
    Stroyakovskiy, Daniil
    Gogas, Helen
    Protsenko, Svetlana
    Pereira, Rodrigo Perez
    Eigentler, Thomas K.
    Rutkowski, Piotr
    Demidov, Lev V.
    Manikhas, Georgy Moiseevich
    Tadesse-Bell, Sara
    Huang, Kuan-Chieh
    McNally, V.
    Mulla, Sohail
    McArthur, Grant A.
    Gutzmer, Ralf
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB plus VEMURAFENIB plus COBIMETINIB COMBINATION IN TREATMENT OF ADULT PATIENTS WITH METASTATIC BRAF-POSITIVE MELANOMA
    Makarova, E.
    Krysanov, I
    Ermakova, V
    Kurkin, D., V
    VALUE IN HEALTH, 2023, 26 (12) : S91 - S91
  • [47] DRESS-Syndrome under systemic Therapy with Vemurafenib plus Cobimetinib in metastatic malignant Melanoma: Report of 5 Patients
    Alar, V
    Oberndoerfer, F.
    Angela, Y.
    Koop, A.
    Satzger, I
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 36 - 37
  • [48] Pembrolizumab for patients with advanced melanoma
    Burki, Talha Khan
    LANCET ONCOLOGY, 2015, 16 (06) : E264 - E264
  • [49] CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma.
    Ribas, Antoni
    Hodi, F. Stephen
    Kurland, John F.
    Shahabi, Vafa
    Francis, Stephen
    Konto, Cyril
    Joe, Andrew K.
    Lainas, Ioannis
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Treatment beyond progression in advanced BRAF-mutated melanoma with vemurafenib and cobimetinib: Results from the BRIM7 trial
    Lewis, K.
    Ribas, A.
    Gonzalez, R.
    Hamid, O.
    Daud, A.
    Puzanov, I.
    Hsu, J.
    Choong, N.
    Koralek, D.
    McArthur, G.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S679 - S679
12345